106 related articles for article (PubMed ID: 20181018)
1. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Saleh HA; Jin B; Barnwell J; Alzohaili O
Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018
[TBL] [Abstract][Full Text] [Related]
2. Proof-of-concept Raman spectroscopy study aimed to differentiate thyroid follicular patterned lesions.
Rau JV; Fosca M; Graziani V; Taffon C; Rocchia M; Caricato M; Pozzilli P; Onetti Muda A; Crescenzi A
Sci Rep; 2017 Nov; 7(1):14970. PubMed ID: 29097686
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Profiles and Blood Biomarkers to Discriminate between Benign Thyroid Nodules and Papillary Carcinoma, Based on UHPLC-QTOF-ESI
Berinde GM; Socaciu AI; Socaciu MA; Petre GE; Socaciu C; Piciu D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542465
[TBL] [Abstract][Full Text] [Related]
4. Finding possible diagnostic markers for differentiating benign and malignant thyroid tumors on example investigate of rheological properties1.
Javakhishvili I; Sanikidze T; Mardaleishvili K; Momtselidze N; Urdulashvili T; Mantskava M; Prantl L; Jung F
Clin Hemorheol Microcirc; 2024 Mar; ():. PubMed ID: 38489170
[TBL] [Abstract][Full Text] [Related]
5. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.
Barut F; Onak Kandemir N; Bektas S; Bahadir B; Keser S; Ozdamar SO
Endocr Pathol; 2010 Jun; 21(2):80-9. PubMed ID: 20198455
[TBL] [Abstract][Full Text] [Related]
6. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Borson-Chazot F; Lifante JC; Sturm N; Lavérriere MH; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2013 Sep; 209(9):585-92. PubMed ID: 23910176
[TBL] [Abstract][Full Text] [Related]
8. Utility of the Growth Differentiation Factor-15 in the Differential Diagnosis of Follicular-Patterned Lesions of the Thyroid on Cytopathologic and Histopathologic Samples.
Perumal PV; Siddaraju N; Saxena SK; Rajendiran S; Bhat RV
Cureus; 2023 Sep; 15(9):e46206. PubMed ID: 37905271
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Expression of HBME-1 and TROP-2 in Some Follicular-Derived Thyroid Lesions.
Abu-Seadah SS; Attiah SM; Ali MY; Shams El-Din M; El-Kholy MA
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2305-2311. PubMed ID: 37505760
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 19 (CK19) expression by thyroid neoplasms in a Nigerian tertiary health centre.
Idowu SA; Olaniyi OO; Oluwole KA
Pan Afr Med J; 2023; 44():176. PubMed ID: 37455890
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms.
Crescenzi A; Baloch Z
Front Endocrinol (Lausanne); 2023; 14():1198099. PubMed ID: 37324272
[TBL] [Abstract][Full Text] [Related]
12. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.
Shonka DC; Ho A; Chintakuntlawar AV; Geiger JL; Park JC; Seetharamu N; Jasim S; Abdelhamid Ahmed AH; Bible KC; Brose MS; Cabanillas ME; Dabekaussen K; Davies L; Dias-Santagata D; Fagin JA; Faquin WC; Ghossein RA; Gopal RK; Miyauchi A; Nikiforov YE; Ringel MD; Robinson B; Ryder MM; Sherman EJ; Sadow PM; Shin JJ; Stack BC; Tuttle RM; Wirth LJ; Zafereo ME; Randolph GW
Head Neck; 2022 Jun; 44(6):1277-1300. PubMed ID: 35274388
[TBL] [Abstract][Full Text] [Related]
13. The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.
Ramkumar S; Sivanandham S
Cureus; 2021 Dec; 13(12):e20339. PubMed ID: 34934597
[TBL] [Abstract][Full Text] [Related]
14. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.
Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014
[TBL] [Abstract][Full Text] [Related]
15. Periostin expression and its supposed roles in benign and malignant thyroid nodules: an immunohistochemical study of 105 cases.
Kusafuka K; Yamashita M; Iwasaki T; Tsuchiya C; Kubota A; Hirata K; Murakami A; Muramatsu A; Arai K; Suzuki M
Diagn Pathol; 2021 Sep; 16(1):86. PubMed ID: 34563225
[TBL] [Abstract][Full Text] [Related]
16. Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules.
Xiong Y; Li X; Liang L; Li D; Yan L; Li X; Di J; Li T
Virchows Arch; 2021 Nov; 479(5):961-974. PubMed ID: 34308507
[TBL] [Abstract][Full Text] [Related]
17. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of TROP-2 and CK19 Expression in Papillary Thyroid Carcinoma in Both Surgical and Cytological Specimens.
Abdou AG; Shabaan M; Abdallha R; Nabil N
Clin Pathol; 2019; 12():2632010X19863047. PubMed ID: 31384753
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma.
Zargari N; Mokhtari M
Eur Thyroid J; 2019 Jan; 8(1):1-6. PubMed ID: 30800635
[TBL] [Abstract][Full Text] [Related]
20. Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid.
Ding L; Jiang Y; Yang W
Pathol Oncol Res; 2019 Apr; 25(2):697-701. PubMed ID: 30539520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
